Literature DB >> 24925819

An assessment of an HIV prevention intervention among people who inject drugs in the states of Manipur and Nagaland, India.

Prabuddhagopal Goswami1, Gajendra Kumar Medhi2, Gregory Armstrong3, Maninder Singh Setia4, Shajan Mathew5, Gay Thongamba5, Lakshmi Ramakrishnan5, Bitra George5, Rakesh Kumar Singh5, Ramesh S Paranjape6, Jagadish Mahanta2.   

Abstract

BACKGROUND: The present study describes an assessment of a large-scale intervention, "Avahan", using an evaluation framework that assesses the program coverage, changes in injection patterns, condom use, and STI and HIV prevalence among People Who Inject Drugs (PWID) in two states of India - Manipur and Nagaland.
METHODS: Program monitoring data and results from two rounds of a cross sectional biological and behavioural surveys in 2006 (Round 1) and 2009 (Round 2) were used. The sample included 839 and 860 PWIDs from Manipur and 821 and 829 PWIDs from Nagaland in Round 1 and Round 2 respectively for current analysis. Bivariate and multivariate analyses were done to measure the changes in behavioural and biological outcomes between the two rounds and to examine the association between programme exposure and behavioural outcomes.
RESULTS: In Manipur, about 77% of the PWIDs were contacted by the peer educators/outreach workers every month and about 18% of the PWIDs visited the clinic every month by March 2010. In Nagaland, however, the proportion of PWIDs visiting the clinic monthly remained low (11% in March 2010). PWIDs in both states were more likely to report 'consistent safe injection practice in the last six months' in Round 2 compared to Round 1 (Manipur: adjusted odds ratio (aOR): 1.88, 95% confidence intervals (CI): 1.46-2.43; Nagaland: aOR: 2.35, 95% CI: 1.86-2.80) PWIDs were also more likely to report consistent condom use with regular partners in Round 2. The prevalence of Hepatitis B virus (HBV) increased in Round 2 in Manipur (11% vs 6%, p<0.001) and Nagaland (8% vs 6%, p=0.05). The prevalence of Hepatitis C virus (HCV) was high and did not change, either in Manipur (67.3% vs 69.9%, p=0.42) and Nagaland (14.7% vs 15.1%, p=0.82). Similarly, the prevalence of HIV did not change significantly between the two Rounds either in Manipur (27.8% in Round 1 vs 29.2% in Round 2, p=0.59) or in Nagaland (1.2% in Round 1 and 1.6% in Round 2 of the IBBA, p=0.82).
CONCLUSION: Improvements in safe injection practices and consistent condom use with regular partners suggest effectiveness of prevention efforts. However, increase in HBV prevalence and non-decline in HCV and HIV prevalence in both the states also underscore the need to continue and intensify targeted interventions (such as Hepatitis B vaccination, needle exchange programmes, condom distribution) for long term risk reduction among PWID population.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CMIS; Condom use; Cross sectional survey; HIV; HIV prevention programme; Hepatitis B&C; Integrated behavioural and biological assessment; Needle/syringe exchange programme; PWID; STI

Mesh:

Year:  2014        PMID: 24925819     DOI: 10.1016/j.drugpo.2014.04.016

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  9 in total

1.  Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.

Authors:  Allison M McFall; Sunil S Solomon; Greg M Lucas; David D Celentano; Aylur K Srikrishnan; Muniratnam S Kumar; Shruti H Mehta
Journal:  Addiction       Date:  2017-04-18       Impact factor: 6.526

Review 2.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Authors:  Lucy Platt; Silvia Minozzi; Jennifer Reed; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Julie Bruneau; Matthew Hickman
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

Review 3.  Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia.

Authors:  Georgios K Nikolopoulos; Evangelia-Georgia Kostaki; Dimitrios Paraskevis
Journal:  Infect Genet Evol       Date:  2016-06-07       Impact factor: 3.342

4.  Factors associated with HIV testing among male injecting drug users: findings from a cross-sectional behavioural and biological survey in Manipur and Nagaland, India.

Authors:  Deepika Ganju; Sowmya Ramesh; Niranjan Saggurti
Journal:  Harm Reduct J       Date:  2016-06-21

5.  Gender Differences in Factors Related to HIV Risk Behaviors among People Who Inject Drugs in North-East India.

Authors:  Bushra Sabri; Allison M McFall; Sunil S Solomon; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Santhanam Anand; David D Celentano; Shruti H Mehta; Suresh Kumar; Gregory M Lucas
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

6.  Changes in HIV prevention programme outcomes among key populations in Kenya: Data from periodic surveys.

Authors:  Helgar Musyoki; Parinita Bhattacharjee; Andrea K Blanchard; Japheth Kioko; Shem Kaosa; John Anthony; Prakash Javalkar; Janet Musimbi; Serah Joy Malaba; Carol Olwande; James F Blanchard; Martin Sirengo; Shajy Isac; Stephen Moses
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

7.  Understanding of HIV/AIDS in the international border area, Manipur: Northeast India.

Authors:  A L Sharma; T R Singh; L S Singh
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

8.  HIV among people who inject drugs in India: a systematic review.

Authors:  Lucy Ngaihbanglovi Pachuau; Caterina Tannous; Mansi Vijaybhai Dhami; Kingsley Emwinyore Agho
Journal:  BMC Public Health       Date:  2022-08-10       Impact factor: 4.135

9.  Analysis of a Targeted Intervention Programme on the Risk Behaviours of Injecting Drug Users in India: Evidence From the National Integrated Biological and Behavioural Surveillance Survey.

Authors:  Damodar Sahu; Varsha Ranjan; Nalini Chandra; Saritha Nair; Anil Kumar; Elangovan Arumugam; Mendu Vishnu Vardhana Rao
Journal:  J Prev Med Public Health       Date:  2022-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.